Skip CCR Main Navigation National Cancer Institute National Cancer Institute U.S. National Institutes of Health
CCR - For Our Staff| Home |

Our Science – Hurwitz Website

Arthur Andrew Hurwitz, Ph.D.

Selected Publications

1)  Shurin MR, Umansky V, Malyguine A, Hurwitz AA, Apte RN, Whiteside T, Jewett A, Thanavala Y, Murphy WJ.
Cellular and molecular pathways in the tumor immunoenvironment: 3rd Cancer Immunotherapy and Immunomonitoring (CITIM) meeting, 22-25 April 2013, Krakow, Poland.
Cancer Immunol. Immunother. 63: 73-80, 2014.
2)  McGray AJ, Hallett R, Bernard D, Swift SL, Zhu Z, Teoderascu F, Vanseggelen H, Hassell JA, Hurwitz AA, Wan Y, Bramson JL.
Immunotherapy-induced CD8+ T cells instigate immune suppression in the tumor.
Mol. Ther. 22: 206-18, 2014.
3)  Zhu Z, Singh V, Watkins SK, Bronte V, Shoe JL, Feigenbaum L, Hurwitz AA.
High-avidity T cells are preferentially tolerized in the tumor microenvironment.
Cancer Res. 73: 595-604, 2013.
4)  Hurwitz AA, Cuss SM, Stagliano KE, Zhu Z.
T Cell Avidity and Tumor Immunity: Problems and Solutions.
Cancer Microenviron. [Epub ahead of print], 2013.
5)  Watkins SK, Hurwitz AA.
FOXO3: A master switch for regulating tolerance and immunity in dendritic cells.
Oncoimmunology. 1: 252-254, 2012.
6)  Hurwitz AA, Watkins SK.
Immune suppression in the tumor microenvironment: a role for dendritic cell-mediated tolerization of T cells.
Cancer Immunol. Immunother. 61: 289-93, 2012.
7)  Watkins SK, Zhu Z, Watkins KE, Hurwitz AA.
Isolation of immune cells from primary tumors.
J Vis Exp. e3952, 2012.
8)  Hudson RS, Yi M, Esposito D, Watkins SK, Hurwitz AA, Yfantis HG, Lee DH, Borin JF, Naslund MJ, Alexander RB, Dorsey TH, Stephens RM, Croce CM, Ambs S.
MicroRNA-1 is a candidate tumor suppressor and prognostic marker in human prostate cancer.
Nucleic Acids Res. 40: 3689-703, 2012.
9)  Hudson RS, Yi M, Esposito D, Glynn SA, Starks AM, Yang Y, Schetter AJ, Watkins SK, Hurwitz AA, Dorsey TH, Stephens RM, Croce CM, Ambs S.
MicroRNA-106b-25 cluster expression is associated with early disease recurrence and targets caspase-7 and focal adhesion in human prostate cancer.
Oncogene. 32: 4139-47, 2012.
10)  Watkins SK, Zhu Z, Riboldi E, Shafer-Weaver KA, Stagliano KE, Sklavos MM, Ambs S, Yagita H, Hurwitz AA.
FOXO3 programs tumor-associated DCs to become tolerogenic in human and murine prostate cancer.
J. Clin. Invest. 121: 1361-72, 2011.
Click Here to View Expanded Bibliography.

This page was last updated on 5/2/2014.